$KaloBios(KBIO)$ "We are very disappointed that KB001-A did not demonstrate a clinically significant effect on Pa infections in these CF patients, but we are thankful to all of them for volunteering to participate in this study," said David W. Pritchard, KaloBios' President and Chief Executive Officer.  "Based on these top line data, we intend to discontinue our development of KB001-A in cystic fibrosis."囊性纤维病还是不好攻克啊，得这种病的人生不如死啊。